Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)
This study aims to investigate the efficacy and safety of PET regimen combined with Chidamide for angioimmunoblastic T cell lymphoma patients.
Angioimmunoblastic T-cell Lymphoma
DRUG: Chidamide
Objective remission rate(ORR), the rate of patients who achieve objective remission after the treatment,including CR (complete remission),CRu (complete remission with unrecovered platelet count) and PR (partial remission)., every 3 months until 24 months after the last patient's enrollment
duration of remission, from date of complete remission to date of progression, relapse, or death from any cause, from the day of remission to the date of first documented progression，up to 24 months after the last patient's enrollment|progression free survival, from date of inclusion to date of progression, relapse, or death from any cause, from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment|overall survival, from the date of inclusion to date of death, irrespective of cause, 24 months after the last patient's enrollment
Patients enrolled in the trial would be given prednisone, etoposide, thalidomide and Chidamide, and the response and side effects are observed and documented.